AUGUST 2, 2021

Biophytis announces Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia

n
    n
  • Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study
    • n
  • Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product
    • n
n
Fullscreen Mode

Other Press Releases

Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half…

Read more

BIOPHYTIS and a Consortium of Investors including RONGHUI RENHE Life Technology Join Forces to Finance and Launch First-Ever Phase 3 Trial in Sarcopenia Creation of a joint venture in Hong…

Read more

Biophytis to Participate in Four Key Events in Q4 2025 Biophytis announces its participation in four major international events that reflect the complementarity of its development strategy: CF&B Midcap Events…

Read more

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners Biophytis announces major progress in preparing its OBA Phase 2 trial…

Read more

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial…

Read more

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Biophytis announces that the European Medicines Agency (EMA) has issued a favorable outcome on Part I of…

Read more